Documents and Memos for CTEP-Supported Trials
CTEP’s memos and guidelines are intended to ensure patient safety while providing the National Cancer Program with the most effective new agent development program possible. Some documents reflect the regulatory requirements of the Food and Drug Administration (FDA) and the Department of Health and Human Services (DHHS). Others have been developed based on policies at the Institute level, consensus among CTEP staff, NCI advisory boards, and leaders in the community of clinical investigators. Specific memos and procedures continue to evolve; through them CTEP, DCTD, NCI aims to provide a flexible, responsive system within the constraints imposed by regulation and the program’s size and scope.
Trial Conduct
- CTEP Investigator's Handbook (PDF)
- NCI Guidelines for Investigators: Adverse Event Reporting Requirements for DCTD (CTEP and CIP) INDs and IDEs (PDF)
- Investigational Agent Management Policies: see the Agent Management page
- Advanced Practice Providers Writing Study Agent Orders (PDF)
- Cyberattack Response Procedures for Site Personnel (PDF)
- RECIST Guidelines (version 1.1)
Lead Organizations: Protocol Design and Conduct
Broadening Eligibility Criteria
- Broadening Eligibility Criteria Guidance (PDF) — May 2024
- Broadening Eligibility Criteria Memo (PDF) — December 2021
Slow Accrual Guidelines
- Early Phase Trial Slow Accrual Guidelines (PDF)
- Slow Accrual Guidelines for Phase 3 Trials (PDF)
- Development of Slow Accrual Guidelines (PDF)
Other LPO Topics
CTEP Program Guidelines and Policies
NCTN
- NCTN Program Guidelines (PDF) — only part 1 applies to the current program
- NCTN Data Sharing Policy (PDF)
- NCTN AYA Publications Guiding Principles (PDF) May 2024
- NCTN PMI Co-Authorship Guidelines (PDF) — February 2023
ETCTN
Memo Archive
Guidance for clinical trials affected by novel coronavirus (2020)
- CTEP/NCORP Interim Coronavirus Guidance (3/13/20)
- CTEP/NCORP Additional Coronavirus Guidance (3/23/20)
- CTEP/NCORP Guidance for COVID-19-Related Adverse Events (3/25/20)
Other Archived Memos
- AUC-Based Dosing for Carboplatin (Oct 22, 2010)